Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis
Year: 2024
Type: article
Abstract: This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.
Source: Pulmonary Circulation
DOI: 10.1002/pul2.12441
Authors: Oksana A. Shlobin, Gary Bruce, Gabriela Gomez‐Rendon, Martha Kingman, Mohammad Rahman, Frances Rogers, Sean Studer, Tobore Tobore, Colleen McEvoy
Language: English
Subfield: Family Practice
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,310
Funder: Actelion Pharmaceuticals
OpenAlex ID: W4403338181